Phase I trial results for oral azacitidine and venetoclax in R/R AML

Phase I trial results for oral azacitidine and venetoclax in R/R AML

A clinical study investigating oral azacitidine plus venetoclax for newly diagnosed and R/R AMLПодробнее

A clinical study investigating oral azacitidine plus venetoclax for newly diagnosed and R/R AML

OMNIVERSE: safety and tolerability of oral azacitidine plus venetoclax in patients with AMLПодробнее

OMNIVERSE: safety and tolerability of oral azacitidine plus venetoclax in patients with AML

Rationale of OMNIVERSE: oral azacitidine + venetoclax in patients with R/R or newly diagnosed AMLПодробнее

Rationale of OMNIVERSE: oral azacitidine + venetoclax in patients with R/R or newly diagnosed AML

Phase I study of ziftomenib with venetoclax or venetoclax/azacitidine or 7+3 in R/R AMLПодробнее

Phase I study of ziftomenib with venetoclax or venetoclax/azacitidine or 7+3 in R/R AML

Phase Ib/II study of magrolimab in combination with azacitidine and venetoclax in patients with AMLПодробнее

Phase Ib/II study of magrolimab in combination with azacitidine and venetoclax in patients with AML

Oral therapies in the future of AML treatmentПодробнее

Oral therapies in the future of AML treatment

Venetoclax plus azacitidine in treatment-naïve and R/R MDSПодробнее

Venetoclax plus azacitidine in treatment-naïve and R/R MDS

Update on Phase I/II study of azacitidine, venetoclax and gilteritinib in patients with FLT3+ AMLПодробнее

Update on Phase I/II study of azacitidine, venetoclax and gilteritinib in patients with FLT3+ AML

Real-world data on venetoclax-based regimens for patients with AML or MDS with excess blasts-2Подробнее

Real-world data on venetoclax-based regimens for patients with AML or MDS with excess blasts-2

Pevonedistat, venetoclax and azacitidine for older AML patientsПодробнее

Pevonedistat, venetoclax and azacitidine for older AML patients

Results from the Phase I SAL-RELAX trial: venetoclax plus cytarabine and mitoxantrone in R/R AMLПодробнее

Results from the Phase I SAL-RELAX trial: venetoclax plus cytarabine and mitoxantrone in R/R AML

Update of a Phase I trial investigating lintuzumab-Ac225 plus venetoclax in R/R AMLПодробнее

Update of a Phase I trial investigating lintuzumab-Ac225 plus venetoclax in R/R AML

Phase Ib study of venetoclax plus azacitidine in patients with R/R MDSПодробнее

Phase Ib study of venetoclax plus azacitidine in patients with R/R MDS

allo-SCT improves survival following venetoclax and azacitidine therapy in AMLПодробнее

allo-SCT improves survival following venetoclax and azacitidine therapy in AML

Azacitidine, venetoclax and gilteritinib in previously untreated and R/R FLT3-mutated AMLПодробнее

Azacitidine, venetoclax and gilteritinib in previously untreated and R/R FLT3-mutated AML

HMA in combination with venetoclax and magrolimab in the treatment of AMLПодробнее

HMA in combination with venetoclax and magrolimab in the treatment of AML

The BLAST AML-2 trial: the addition of pembrolizumab to azacitidine and venetoclax in AMLПодробнее

The BLAST AML-2 trial: the addition of pembrolizumab to azacitidine and venetoclax in AML

Venetoclax in AML updates: approval & combinationsПодробнее

Venetoclax in AML updates: approval & combinations

Phase II study of venetoclax and azacitidine vs induction chemotherapy in fit patients with AMLПодробнее

Phase II study of venetoclax and azacitidine vs induction chemotherapy in fit patients with AML

Новости